glesatinib
Small moleculeexperimental
Glesatinib (MGCD265) is an experimental anti-cancer drug. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02954991)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
- Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
FLT1 inhibitor
MST1R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccc(F)cc5)cc4F)c3s2)nc1- Mol. weight
- 619.72 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGlesatinib ↗
- ChEMBLCHEMBL3989914 ↗
Also known as
- glesatinib
- glesatinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02954991 | Phase 2 | Nov 1, 2016 | Mirati Therapeutics Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mirati Therapeutics Inc. | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1